| 0 (0%) | 12-26 18:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.23 | 1-year : | 1.46 |
| Resists | First : | 1.05 | Second : | 1.25 |
| Pivot price | 0.85  |
|||
| Supports | First : | 0.75 | Second : | 0.62 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.88 |
| MA(100) : | 1.59 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 2.8 |
| RSI | RSI(14): 31 |
|||
| 52-week | High : | 3.28 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CASI ] has closed above bottom band by 24.5%. Bollinger Bands are 64.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.83 | 0.83 - 0.83 |
| Low: | 0.74 - 0.75 | 0.75 - 0.75 |
| Close: | 0.78 - 0.79 | 0.79 - 0.8 |
Fri, 26 Dec 2025
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules - MSN
Tue, 23 Dec 2025
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026 - TipRanks
Tue, 23 Dec 2025
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension - Investing.com
Tue, 23 Dec 2025
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - ACCESS Newswire
Tue, 23 Dec 2025
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - The Joplin Globe
Tue, 23 Dec 2025
CASI Pharmaceuticals gets extra time to stay on Nasdaq - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 15 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 54.7 (%) |
| Held by Institutions | 17.1 (%) |
| Shares Short | 101 (K) |
| Shares Short P.Month | 137 (K) |
| EPS | -3.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.39 |
| Profit Margin | -184 % |
| Operating Margin | -333.2 % |
| Return on Assets (ttm) | -61.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -60.5 % |
| Gross Profit (p.s.) | 0.62 |
| Sales Per Share | 1.73 |
| EBITDA (p.s.) | -2.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.27 |
| PEG Ratio | 0 |
| Price to Book value | -0.57 |
| Price to Sales | 0.45 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|